Company news

Immuron Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Immuron achieves record Travelan sales

February 12, 2024

Immuron achieves record half yearly Travelan sales

January 15, 2024

First Patients Enrolled in Campylobacter Clinical Study

December 4, 2023

Immuron achieves record quarterly Travelan sales

October 11, 2023

Immuron achieves record monthly Travelan sales

September 13, 2023

Immuron Receives TGA GMP Clearance

August 9, 2023

Immuron enrols patients in Travelan clinical study

July 24, 2023

Immuron FY23 Sales increase 136% on FY22 Sales

July 5, 2023

Immuron Initiates Recruitment of Travelan Clinical Study

May 30, 2023

FDA Removed Clinical Hold on Campylobacter ETEC Therapeutic

May 7, 2023

Q3 FY23 Business Update Presentation

April 18, 2023

Immuron Q3 Sales reach 150% of 1H Sales

April 5, 2023

Business Update Presentation

February 27, 2023

Immuron Receives FDA Approval for Travelan IND Application

December 22, 2022

Immuron completes strategic investment in Ateria Health

November 15, 2022

IMC investment in leading gut health biotech Ateria Health

October 13, 2022

Immuron Update on IMM-124E SARS-CoV-2 Research

August 18, 2022

North American Travelan Sales up 494%, Global sales up 431%

July 10, 2022

European Patent Notification on Drug Composition for CDI

July 6, 2022

US DoD NMRC files IND application with FDA

May 11, 2022

US DoD Uniformed Services University Clinical Update

May 9, 2022

Appointment of Mr Steven Lydeamore as Chef Executive Officer

May 5, 2022

Immuron Q3 Global Sales up 216% YoY

April 27, 2022

Half Yearly Report and Accounts

February 25, 2022

Response to ASX Query

January 24, 2022

Immuron Receives European Patent on Drug to Treat Diarrhea

January 12, 2022

US DoD Travelan Clinical Update

November 14, 2021

US DoD Naval Medical Research Center Clinical Update

November 9, 2021

IMM124E Demonstrates Antiviral T-Cell Immunity

October 8, 2021

Reinstatement to Official Quotation

September 23, 2021

Immuron planned Acquisition of R&D Vaccine Company

September 23, 2021

Preliminary Final Report

August 31, 2021

Voluntary Suspension

May 30, 2021

Pause in Trading

May 27, 2021

IMM124E May Offer New Modality for Inhibition of SARS-CoV-2

May 12, 2021

Immuron SARS-CoV-2 Research Agreement with Monash University

December 14, 2020

Immuron Receives AUD $358,280 R&D Tax Concession Refund

November 23, 2020

US DoD NMRC Reports Positive Response to Vaccine

November 8, 2020

Immuron Travelers Diarrhea Market Update

October 12, 2020

Appendix 4E and 2020 Financial Report

August 31, 2020

Immuron Announces US$20.0 Million Registered Direct Offering

July 21, 2020

Immuron Reports Neutralizing activity Against SARS-CoV-2

July 21, 2020

US DoD Receives FDA Guidance on clinical development plans

July 20, 2020

IMC & CSIRO to produce oral therapeutic for DoD evaluation

June 19, 2020

Response to ASX Price Query

June 10, 2020

Immuron Global Sales Up 60%

April 20, 2020

Resignation of Managing Director and cuts amid Covid19

March 24, 2020

North American Travelan sales up 98% to Dec 2019

January 27, 2020

Immuron Plans IMM-124E Trial to Prevent Travelers Diarrhea

November 20, 2019

Immuron Receives AUD $0.53M R&D Tax Concession Refund

November 3, 2019

← Newer news releases · Older news releases →

Decks

The 5 newest of 105 decks. Every deck is listed under its year.